FDA awards ODD status to Sanofi's rilzabrutinib for two rare conditions

FDA awards ODD status to Sanofi's rilzabrutinib for two rare conditions
Sanofi's rilzabrutinib, a BTK inhibitor, received FDA orphan drug designation for treating IgG4-related disease and warm autoimmune haemolytic anaemia. Promising results from Phase II trials show potential benefits for patients.